Connection
Rajesh Agarwal to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Rajesh Agarwal has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
Connection Strength |
|
 |
|
 |
|
0.701 |
|
|
|
-
Deep G, Agarwal R. New combination therapies with cell-cycle agents. Curr Opin Investig Drugs. 2008 Jun; 9(6):591-604.
Score: 0.161
-
Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin. 2007 Sep; 28(9):1466-75.
Score: 0.153
-
Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res. 2004 Dec 15; 10(24):8641-7.
Score: 0.127
-
Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer. 2003 Sep 20; 106(5):699-705.
Score: 0.116
-
Punia R, Raina K, Agarwal R, Singh RP. Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells. PLoS One. 2017; 12(8):e0182870.
Score: 0.076
-
Agarwal R, Deep G. Kava, a tonic for relieving the irrational development of natural preventive agents. Cancer Prev Res (Phila). 2008 Nov; 1(6):409-12.
Score: 0.041
-
Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res. 2002 Nov; 8(11):3512-9.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|